ES2163742T3 - Quinoxalinadionas. - Google Patents
Quinoxalinadionas.Info
- Publication number
- ES2163742T3 ES2163742T3 ES97908156T ES97908156T ES2163742T3 ES 2163742 T3 ES2163742 T3 ES 2163742T3 ES 97908156 T ES97908156 T ES 97908156T ES 97908156 T ES97908156 T ES 97908156T ES 2163742 T3 ES2163742 T3 ES 2163742T3
- Authority
- ES
- Spain
- Prior art keywords
- rent
- ring
- alcoxi
- sub
- arilo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 abstract 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 abstract 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000626 neurodegenerative effect Effects 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000007921 spray Substances 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Luminescent Compositions (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Abstract
LA INVENCION PROPORCIONA COMPUESTOS DE FORMULA (I) Y LAS SALES FARMACEUTICAMENTE ACEPTABLES DE LOS MISMOS, EN LA QUE R ES UN GRUPO HETEROARILO CON UN ANILLO DE 5 ESLABONES QUE CONTIENEN 3 O 4 HETEROATOMOS DE NITROGENO, EL CUAL ESTA UNIDO AL ANILLO DE QUINOXALINDIONA MEDIANTE UN ATOMO DE CARBONO O DE NITROGENO DEL ANILLO, O ES UN GRUPO HETEROARILO CON UN ANILLO DE 6 ESLABONES QUE CONTIENEN ENTRE 1 Y 3 HETEROATOMOS DE NITROGENO QUE ESTA UNIDO AL ANILLO DE QUINOXALINDIONA MEDIANTE UN ATOMO DE CARBONO DEL ANILLO, ESTANDO DICHOS GRUPOS OPCIONALMENTE BENZO CONDENSADOS Y OPCIONALMENTE SUSTITUIDOS, INCLUYENDO EN LA PORCION BENZO CONDENSADA, MEDIANTE 1 O 2 SUSTITUYENTES, SELECCIONADO CADA UNO DE ELLOS INDEPENDIENTEMENTE ENTRE ALQUILO C SUB,1 -C 4 , ALQUENILO C 2 -C 4 , CICLOALQUILO C 3 -C 7 , HALOGENO, HIDROXI, ALCOXI C 1 -C 4 , OXICICLOALQUILO C 3 -C 7 , -COOH, ALCOXICARBONILO C 1 -C 4 , CONR 3 R 4 , -N 3 R 4 , -S(O) P(ALQUILO C 1 -C 4 ), -SO 2 NR 3 R 4 , ARI LO, OXIARILO, ARILALCOXI (C 1 -C 4 ) YHET, ESTANDO DICHO ALQUILO C 1 -C 4 OPCIONALMENTE SUSTITUIDO CON CIC LOALQUILO C 3 -C 7 , HALOGENO, HIDROXI, ALCOXI C 1-C 4 , HALOALCOXI (C 1 -C 4 ), OXICICLOALQUILO C SUB,3 C 7 , CICLOALQUIL C 3 -C 7 ALCOXI C 1 C4 ), -COOH, ALCOXI C 1 -C 4 CARBONILO, CONR 3 R 4 , -NR 3 R 4 , -S(O) P (ALQUILO C 1 -C 4 ), - SO 2 (ARILO), SO 2 NR 3 R 4 , MOR FOLINO, ARILO, OXIARILO, ARILALCOXI (C 1 -C 4 ) O HET, ESTANDO DICHO ALQUENILO C 2 -C 4 OPCIONALMENTE SUSTITUIDO CON ARILO; R 1 Y R 2 SE SELECCIONAN CADA UNO DE ELLOS INDEPENDIENTEMENTE ENTRE H, FLUORO, CLORO, BROMO, ALQUILO C 1 -C SUB.4 Y HALOALQUILO C 1 -C SUB.4 ; R 3 Y R 4 SE SELECCIONAN CADA UNO DE ELLOS INDEPENDIENTEMENTE ENTRE H Y ALQUILO C 1 C 4 O, CUANDO SE UNEN, SON ALQUI LENO C 5 -C 7 ; P ES 0, 1 O 2; JUNTO CON LA PREPARACION DE LAS COMPOSICIONES QUE LOS CONTIENEN, LOS USOS DE Y LOS INTERMEDIOS UTILIZADOS EN LA SINTESIS DE DICHOS COMPUESTOS. LOS COMPUESTOS SON UTILES COMO ANTAGONISTAS DEL RECEPTOR DE LA NMDA PARA EL TRATAMIENTO DE TRASTORNOS NEURODEGENERATIVOS AGUDOS Y NEUROLOGICOS CRONICOS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9605027.3A GB9605027D0 (en) | 1996-03-09 | 1996-03-09 | Quinoxalinediones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2163742T3 true ES2163742T3 (es) | 2002-02-01 |
Family
ID=10790134
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES97908156T Expired - Lifetime ES2163742T3 (es) | 1996-03-09 | 1997-02-27 | Quinoxalinadionas. |
Country Status (42)
| Country | Link |
|---|---|
| US (1) | US6376490B1 (es) |
| EP (1) | EP0885212B1 (es) |
| JP (1) | JP3110467B2 (es) |
| KR (1) | KR100288099B1 (es) |
| CN (1) | CN1103770C (es) |
| AP (1) | AP767A (es) |
| AR (1) | AR006119A1 (es) |
| AT (1) | ATE208773T1 (es) |
| AU (1) | AU717972B2 (es) |
| BG (1) | BG63340B1 (es) |
| BR (1) | BR9707851A (es) |
| CA (1) | CA2248366C (es) |
| CO (1) | CO4770976A1 (es) |
| CZ (1) | CZ292792B6 (es) |
| DE (1) | DE69708269T2 (es) |
| DK (1) | DK0885212T3 (es) |
| DZ (1) | DZ2188A1 (es) |
| EA (1) | EA001730B1 (es) |
| ES (1) | ES2163742T3 (es) |
| GB (1) | GB9605027D0 (es) |
| HN (1) | HN1998000034A (es) |
| HR (1) | HRP970132A2 (es) |
| HU (1) | HUP9900975A3 (es) |
| ID (1) | ID18112A (es) |
| IL (1) | IL125491A (es) |
| IS (1) | IS4811A (es) |
| MA (1) | MA26422A1 (es) |
| NO (1) | NO984058L (es) |
| NZ (1) | NZ331060A (es) |
| OA (1) | OA10850A (es) |
| PE (2) | PE43398A1 (es) |
| PL (1) | PL329032A1 (es) |
| PT (1) | PT885212E (es) |
| SI (1) | SI0885212T1 (es) |
| SK (1) | SK283467B6 (es) |
| TN (1) | TNSN97044A1 (es) |
| TR (1) | TR199801782T2 (es) |
| TW (1) | TW454004B (es) |
| UY (1) | UY24482A1 (es) |
| WO (1) | WO1997032873A1 (es) |
| YU (2) | YU39698A (es) |
| ZA (1) | ZA971987B (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ336842A (en) * | 1997-02-27 | 2000-05-26 | Pfizer | Process of making quinoxalinediones to produce antagonistic effect at NMDA receptors |
| AP982A (en) * | 1997-02-27 | 2001-07-16 | Pfizer | Quinoxalinediones. |
| US6340758B1 (en) * | 1997-05-16 | 2002-01-22 | Warner-Lambert Company | Conformationally semi-constrained quinoxaline 2,3-diones as neuroprotective agents |
| DE10005150A1 (de) * | 2000-02-07 | 2001-08-09 | Merck Patent Gmbh | Verfahren zur Herstellung von 5-Arylnicotinaldehyden |
| CA2409819C (en) * | 2000-05-19 | 2009-09-15 | Yamanouchi Pharmaceutical Co., Ltd. | Triazole derivatives |
| US7732162B2 (en) | 2003-05-05 | 2010-06-08 | Probiodrug Ag | Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases |
| WO2005006945A2 (en) * | 2003-07-03 | 2005-01-27 | The Salk Institute For Biological Studies | Methods for treating neural disorders and compounds useful therefor |
| MY145368A (en) | 2004-01-13 | 2012-01-31 | Nissan Chemical Ind Ltd | Aminoquinoxaline compounds and polyaminoquinoxaline compounds, and use thereof |
| US7799894B2 (en) | 2004-02-06 | 2010-09-21 | Yamaguchi University | Electrode for energy storage device and process for producing the same |
| JP2007223901A (ja) * | 2004-03-24 | 2007-09-06 | Takeda Chem Ind Ltd | 複素環化合物およびその用途 |
| US20060211739A1 (en) * | 2005-02-08 | 2006-09-21 | Arturo Perez-Medrano | Use of selective P2X7 receptor antagonists |
| WO2007112347A1 (en) * | 2006-03-28 | 2007-10-04 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
| WO2008055945A1 (en) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases |
| WO2008065141A1 (en) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Novel inhibitors of glutaminyl cyclase |
| CA2686816A1 (en) | 2007-01-16 | 2008-07-24 | The Johns Hopkins University | Use of various glutamate receptor antagonists for delaying or preventing platelet activity or for treating or preventing a thrombotic disease or disorder |
| EP2481408A3 (en) | 2007-03-01 | 2013-01-09 | Probiodrug AG | New use of glutaminyl cyclase inhibitors |
| EP2865670B1 (en) | 2007-04-18 | 2017-01-11 | Probiodrug AG | Thiourea derivatives as glutaminyl cyclase inhibitors |
| CN101679383B (zh) * | 2007-05-17 | 2014-10-29 | 株式会社半导体能源研究所 | 三唑衍生物，和使用三唑衍生物的发光元件、发光器件和电子器件 |
| US8486940B2 (en) | 2009-09-11 | 2013-07-16 | Probiodrug Ag | Inhibitors |
| JP6026284B2 (ja) | 2010-03-03 | 2016-11-16 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤 |
| EP2545047B9 (en) | 2010-03-10 | 2015-06-10 | Probiodrug AG | Heterocyclic inhibitors of glutaminyl cyclase (qc, ec 2.3.2.5) |
| EP2560953B1 (en) | 2010-04-21 | 2016-01-06 | Probiodrug AG | Inhibitors of glutaminyl cyclase |
| JP6050264B2 (ja) | 2011-03-16 | 2016-12-21 | プロビオドルグ エージー | グルタミニルシクラーゼの阻害剤としてのベンゾイミダゾール誘導体 |
| US9879004B2 (en) * | 2013-02-07 | 2018-01-30 | Merck Patent Gmbh | Substituted acetylene derivatives and their use as positive allosteric modulators of mGluR4 |
| PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
| CN111548320B (zh) * | 2019-10-09 | 2023-03-24 | 贵州大学 | 一类1，3，4-噁二唑酰肼类化合物及其制备方法和应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69132340T2 (de) * | 1990-11-06 | 2001-02-08 | Yamanouchi Pharmaceutical Co., Ltd. | Kondensiertes pyrazinderivat |
| DE4217952A1 (de) * | 1992-05-30 | 1993-12-02 | Basf Ag | Chinoxalin-2,3(1H,4H)-dione |
| GB9418443D0 (en) | 1994-09-13 | 1994-11-02 | Pfizer Ltd | Therapeutic agents |
| DE4439492A1 (de) * | 1994-10-25 | 1996-05-02 | Schering Ag | Neue Chinoxalindionderivate, deren Herstellung und Verwendung in Arzneimitteln |
| NZ336842A (en) * | 1997-02-27 | 2000-05-26 | Pfizer | Process of making quinoxalinediones to produce antagonistic effect at NMDA receptors |
-
1996
- 1996-03-09 GB GBGB9605027.3A patent/GB9605027D0/en active Pending
-
1997
- 1997-02-05 TW TW086101412A patent/TW454004B/zh not_active IP Right Cessation
- 1997-02-27 JP JP09531429A patent/JP3110467B2/ja not_active Expired - Fee Related
- 1997-02-27 EP EP97908156A patent/EP0885212B1/en not_active Expired - Lifetime
- 1997-02-27 DK DK97908156T patent/DK0885212T3/da active
- 1997-02-27 CN CN97192923A patent/CN1103770C/zh not_active Expired - Fee Related
- 1997-02-27 AT AT97908156T patent/ATE208773T1/de not_active IP Right Cessation
- 1997-02-27 ES ES97908156T patent/ES2163742T3/es not_active Expired - Lifetime
- 1997-02-27 DE DE69708269T patent/DE69708269T2/de not_active Expired - Fee Related
- 1997-02-27 PT PT97908156T patent/PT885212E/pt unknown
- 1997-02-27 SK SK1214-98A patent/SK283467B6/sk unknown
- 1997-02-27 KR KR1019980707063A patent/KR100288099B1/ko not_active IP Right Cessation
- 1997-02-27 TR TR1998/01782T patent/TR199801782T2/xx unknown
- 1997-02-27 NZ NZ331060A patent/NZ331060A/xx unknown
- 1997-02-27 CZ CZ19982864A patent/CZ292792B6/cs not_active IP Right Cessation
- 1997-02-27 CA CA002248366A patent/CA2248366C/en not_active Expired - Fee Related
- 1997-02-27 YU YU39698A patent/YU39698A/sh unknown
- 1997-02-27 BR BR9707851A patent/BR9707851A/pt not_active Application Discontinuation
- 1997-02-27 IL IL12549197A patent/IL125491A/xx not_active IP Right Cessation
- 1997-02-27 EA EA199800702A patent/EA001730B1/ru not_active IP Right Cessation
- 1997-02-27 WO PCT/EP1997/000995 patent/WO1997032873A1/en active IP Right Grant
- 1997-02-27 AU AU20231/97A patent/AU717972B2/en not_active Ceased
- 1997-02-27 HU HU9900975A patent/HUP9900975A3/hu unknown
- 1997-02-27 SI SI9730225T patent/SI0885212T1/xx unknown
- 1997-02-27 PL PL97329032A patent/PL329032A1/xx unknown
- 1997-03-05 DZ DZ970034A patent/DZ2188A1/fr active
- 1997-03-05 MA MA24514A patent/MA26422A1/fr unknown
- 1997-03-05 AR ARP970100888A patent/AR006119A1/es unknown
- 1997-03-05 TN TNTNSN97044A patent/TNSN97044A1/fr unknown
- 1997-03-06 PE PE1997000162A patent/PE43398A1/es not_active Application Discontinuation
- 1997-03-06 AP APAP/P/1997/000947A patent/AP767A/en active
- 1997-03-06 UY UY24482A patent/UY24482A1/es not_active IP Right Cessation
- 1997-03-07 HR HR9605027.3A patent/HRP970132A2/xx not_active Application Discontinuation
- 1997-03-07 ID IDP970725A patent/ID18112A/id unknown
- 1997-03-07 ZA ZA971987A patent/ZA971987B/xx unknown
- 1997-03-10 CO CO97012901A patent/CO4770976A1/es unknown
-
1998
- 1998-02-19 HN HN1998000034A patent/HN1998000034A/es unknown
- 1998-02-23 PE PE1998000128A patent/PE58199A1/es not_active Application Discontinuation
- 1998-02-24 YU YU41199A patent/YU41199A/sh unknown
- 1998-07-27 IS IS4811A patent/IS4811A/is unknown
- 1998-08-28 OA OA9800155A patent/OA10850A/en unknown
- 1998-09-03 NO NO984058A patent/NO984058L/no unknown
- 1998-09-04 US US09/157,806 patent/US6376490B1/en not_active Expired - Fee Related
- 1998-09-09 BG BG102760A patent/BG63340B1/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2163742T3 (es) | Quinoxalinadionas. | |
| ES2151652T3 (es) | Derivados de indol como antagonistas del receptor 5ht. | |
| PA8550401A1 (es) | Compuestos de heteroarilo biciclicos fusionados substituidos con heteroarilo como ligando del receptor gaba | |
| ES2194205T3 (es) | Derivados de triazolo-piridazina sustituidos como ligandos para los receptores gaba. | |
| PE20081192A1 (es) | Tratamiento del dolor | |
| DK1379525T3 (da) | Heteropolycykliske forbindelser og anvendelse deraf som metabotropiske glutamatreceptor-antagonister | |
| ES2175350T3 (es) | Compuestos triciclicos que tienen afinidad de union a receptores de melatonina, su produccion y uso. | |
| UY27322A1 (es) | Nuevos derivados de indol con afinidad por el receptor 5-ht6 | |
| ES2157366T3 (es) | Derivados de pirimidindiona, pirimidintriona, triacindiona como antagonistas de receptores alfa-1-adrenergicos. | |
| ES2158314T3 (es) | Oximas, hidrazonas y olefinas sustituidas como antagonistas de la neuroquinina. | |
| ES2194844T3 (es) | Antagonistas del receptor de aminoacidos excitadores. | |
| PA8547901A1 (es) | Derivados de 4-piperacinilindol con afinidad receptora de 5-ht6 | |
| ECSP034640A (es) | Derivados de feniletenilo o feniletinilo como antagonistas del receptor del glutamato | |
| UY26874A1 (es) | Compuestos heterocíclicos como ligandos de los receptores gaba | |
| GT200500367A (es) | Derivados novedosos pirrolidilo de compuestos heteroaromaticos | |
| MX19448A (es) | Procedimiento para la prreparacion de compuestos antagonistas de los receptores de aminoacidos excitadores; compuestos obtenidos y composicion farmaceutica que los incluye. | |
| MX9303263A (es) | Antagonistas de la angiotensina ii, procedimiento para su preparacion y formulaciones farmaceuticas que los contienen | |
| UY30954A1 (es) | Dihidro y tetrahidro oxazolopirimidinonas sustituidas, preparacion y uso de las mismas | |
| ES2161231T3 (es) | Compuestos heterociclicos como antagonistas de bradiquinina. | |
| PE20080192A1 (es) | PIRIDIN[3,4-b]PIRAZINONAS | |
| DK0640592T3 (da) | N-acylerede tricycliske azaheteroringe anvendelige som vasopressin-antagonister | |
| GT200600165A (es) | Derivados dihidrobenzofuranos y usos de los mismos | |
| BRPI0516467A (pt) | derivados indol 5-sulfonil-1-piperidinil substituìdos como antagonistas de receptor de 5-ht6 para o tratamento de distúrbios do snc | |
| UY25300A1 (es) | Composiciones conteniendo un antagonista alfa adrenérgico y un compuesto que eleva los niveles de cgmp para el tratamiento de la impotencia | |
| ES2180041T3 (es) | Derivados de 5-oxido de piridazino(4,5-b)quinoleina, su preparacion y su uso como antagonistas de glicina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 885212 Country of ref document: ES |